Cantor Fitzgerald maintains Merck & Co at Neutral, raises price target to $155 from $145

What happened

Cantor Fitzgerald maintained its Neutral rating on Merck & Co and raised its price target to $155 from $145. The new target is 6.9% higher and implies 3.7% upside from Merck’s October 30 closing price of $149.52.

Confirmed

Global impact / market context

The higher target reflects a more favorable valuation estimate from Cantor, but the unchanged Neutral rating signals no shift in its overall stance. If investors act on the target, buying or selling could affect Merck’s share price, although the article reports no resulting trading response.

Analyst inference

The five most recent analyst notes in the article place Merck price targets between $140 and $180, with Cantor’s $155 target within that range. Differences in these estimates reflect varied analyst views, but they do not establish Merck’s future share price or actual investor returns.

Confirmed

What to watch

1. Check whether Cantor changes its Neutral rating or $155 target in later research; a revision could alter investor expectations and buying or selling of Merck shares. Analyst inference
2. Compare future Merck price targets with the cited $140–$180 range; movement beyond it could indicate analysts are revising their estimates of the company’s value. Analyst inference
3. Watch Merck’s share price relative to the $155 target and October 30 close of $149.52; the article gives no later price or investor response. Analyst inference

Evidence

• Original source link unavailable